SCHEMBL30516650

SCHEMBL30516650

COc1cccc(N2CCC2=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.55
MGLL Q99685 1/20 0.54
MAPT P10636 2/20 0.53
ADRB1 P08588 1/20 0.51
DRD2 P14416 3/20 0.51
DRD3 P35462 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
CTSG P08311 1/20 0.48
CMA1 P23946 1/20 0.48
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366082 1.00 ALOX5 (0.55) ALOX5MGLLMAPTADRB1DRD2
SCHEMBL11116125 0.92 NPC1 (0.60) ALOX5MGLLDRD2DRD3NPC1
SCHEMBL21504279 0.90 NPC1 (0.56) ALOX5MGLLMAPTDRD2DRD3
SCHEMBL25079569 0.82 DDB1 (0.66) ALOX5MGLLMAPTADRB1DRD2
SCHEMBL2046118 0.81 POLB (0.61) MGLLMAPTADRB1NPC1RAB9A
SCHEMBL1663489 0.81 ADRB1 (0.59) ALOX5MGLLMAPTADRB1DRD2
SCHEMBL5736692 0.81 CTSG (0.51) MGLLNPC1RAB9ACTSGCMA1
SCHEMBL9564052 0.80 L3MBTL1 (0.62) ALOX5MGLLMAPTADRB1DRD2
Hydrochloric Acid SCHEMBL1584087 0.80 ADRB1 (0.57) ALOX5MGLLMAPTADRB1DRD2
SCHEMBL26784122 0.79 FFAR4 (0.42) ALOX5MAPTCYP11B1CYP11B2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119013017-A Pharmaceutical composition for treating cancer comprising an anticancer agent and a novel compound having an inhibitory activity on prostaglandin E2 receptor 治纳辅医药科技有限公司 2024-11-22 CN disclosed
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 WO disclosed
CN-116529238-A Novel prostaglandin E 2 Compounds with receptor inhibiting activity and uses thereof 治纳辅医药科技有限公司 2023-08-01 CN disclosed